SG11201407239SA - BI-FUNCTIONAL SHORT-HAIRPIN RNA (BI-SHRNA) SPECIFIC FOR SINGLE-NUCLEOTIDE <i>KRAS</i> MUTATIONS - Google Patents
BI-FUNCTIONAL SHORT-HAIRPIN RNA (BI-SHRNA) SPECIFIC FOR SINGLE-NUCLEOTIDE <i>KRAS</i> MUTATIONSInfo
- Publication number
- SG11201407239SA SG11201407239SA SG11201407239SA SG11201407239SA SG11201407239SA SG 11201407239S A SG11201407239S A SG 11201407239SA SG 11201407239S A SG11201407239S A SG 11201407239SA SG 11201407239S A SG11201407239S A SG 11201407239SA SG 11201407239S A SG11201407239S A SG 11201407239SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- dallas
- ras
- rna
- drive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/170071 A1 (51) International Patent Classification: C12N15/113 (2010.01) C12N15/85 (2006.01) A61K 48/00 (2006.01) A ft IK 9/127 (2006.01) A61P 35/00 (2006.01) B82Y 5/00 (2011.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/040407 9 May 2013 (09.05.2013) English (30) Priority Data: 61/644,875 13/890,957 9 May 2012 (09.05.2012) 9 May 2013 (09.05.2013) English US US (71) Applicant: GRADALIS, INC. [US/US]; 2545 Golden Bear Drive, Suite 110, Carollton, TX 75006 (US). (72) Inventors: RAO, Donald; 3355 Blackburn Street, Dallas, TX 75204 (US). WANG, Zhaohui; 4210 Valleywood Drive, Grapevine, TX 76051 (US). NEMUNAITIS, John J.; 1136 Mallard Pointe Drive, Cedar Hill, TX 75104-6911 (US). SENZER, Neil; 8 Milford Place, Dallas, TX 75230 (US). (74) Agents: CHALKER, Daniel J. et al.; Chalker Flores, LLP, 14951 North Dallas Parkway, Suite 400, Dallas, TX 75254 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: BI-FUNCTIONAL SHORT-HAIRPIN RNA (BI-SHRNA) SPECIFIC FOR SINGLE-NUCLEOTIDE KRAS MUTA TIONS SamHS 4A5-1 SViKHt-S sxiyfA) l> o o l> i-H en HSV-TK W?4 Prrsii! A / \ SgSi / v FIG. 1 o CJ (57) Abstract: The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of K-ras a gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA Q molecule located within is the K-ras gene and wherein the bifunctional RNA molecule is capable of activating cleavage-dependent a and cleavage-independent RNA-induced silencing a complex for reducing the expression level of K-ras.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644875P | 2012-05-09 | 2012-05-09 | |
US13/890,957 US9353373B2 (en) | 2012-05-09 | 2013-05-09 | Bi-functional short-hairpin RNA (bi-shRNA) specific for single-nucleotide KRAS mutations |
PCT/US2013/040407 WO2013170071A1 (en) | 2012-05-09 | 2013-05-09 | Bi-functional short-hairpin rna (bi-shrna) specific for single-nucleotide kras mutations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407239SA true SG11201407239SA (en) | 2014-12-30 |
Family
ID=49548788
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407239SA SG11201407239SA (en) | 2012-05-09 | 2013-05-09 | BI-FUNCTIONAL SHORT-HAIRPIN RNA (BI-SHRNA) SPECIFIC FOR SINGLE-NUCLEOTIDE <i>KRAS</i> MUTATIONS |
Country Status (13)
Country | Link |
---|---|
US (2) | US9353373B2 (en) |
EP (1) | EP2847333A4 (en) |
JP (2) | JP6283661B2 (en) |
KR (1) | KR20150006477A (en) |
CN (1) | CN104685055A (en) |
AR (1) | AR091004A1 (en) |
AU (1) | AU2013259387B2 (en) |
CA (1) | CA2872930A1 (en) |
IL (1) | IL235486A0 (en) |
MX (1) | MX2014013475A (en) |
SG (1) | SG11201407239SA (en) |
TW (1) | TW201402813A (en) |
WO (1) | WO2013170071A1 (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8252526B2 (en) * | 2006-11-09 | 2012-08-28 | Gradalis, Inc. | ShRNA molecules and methods of use thereof |
WO2011079077A1 (en) | 2009-12-23 | 2011-06-30 | Gradalis, Inc. | Furin-knockdown and gm-csf-augmented (fang) cancer vaccine |
AR091004A1 (en) * | 2012-05-09 | 2014-12-30 | Gradalis Inc | RNA IN SHORT BIFUNCTIONAL FORK (BI-ARNHC) SPECIFIC OF INDIVIDUAL NUCLEOTID MUTATIONS IN K-RAS |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
TWI659021B (en) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Inhibitors of kras g12c |
US11885816B2 (en) * | 2013-11-26 | 2024-01-30 | University Of North Texas Health Science Center At Forth Worth | Personalized medicine approach for treating cognitive loss |
LU92353A1 (en) * | 2014-01-14 | 2015-07-15 | Univ Muenster Wilhelms | Antibody-mediated delivery of RNAI |
AU2015249265A1 (en) * | 2014-04-25 | 2016-11-03 | Baylor College Of Medicine | Multiple targeted RNAi for the treatment of cancers |
CN106661576A (en) * | 2014-04-25 | 2017-05-10 | 斯特里克生物公司 | Multiple targeted rnai for the treatment of cancers |
JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
EP3197870B1 (en) | 2014-09-25 | 2020-08-19 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
JP6789239B2 (en) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Condensation tricyclic inhibitor of KRAS and method of its use |
AU2016275046B2 (en) * | 2015-06-10 | 2022-07-28 | Board Of Regents, The University Of Texas System | Use of exosomes for the treatment of disease |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
WO2017087528A1 (en) | 2015-11-16 | 2017-05-26 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
EP3445392A1 (en) * | 2016-04-22 | 2019-02-27 | CureVac AG | Rna encoding a tumor antigen |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
CN110036010A (en) | 2016-09-29 | 2019-07-19 | 亚瑞克西斯制药公司 | The inhibitor of KRAS G12C mutain |
WO2018068017A1 (en) | 2016-10-07 | 2018-04-12 | Araxes Pharma Llc | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
WO2018098352A2 (en) * | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
EP3573967A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused hetero-hetero bicyclic compounds and methods of use thereof |
CN117224710A (en) * | 2017-02-01 | 2023-12-15 | 莫得纳特斯公司 | Immunomodulatory therapeutic MRNA compositions encoding mutant peptides that activate oncogenes |
KR20200010306A (en) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Covalent Inhibitors of KRAS |
US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
WO2018225873A1 (en) * | 2017-06-09 | 2018-12-13 | 協和発酵キリン株式会社 | Nucleic-acid-containing nanoparticles |
CA3072329A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
SG11202008433QA (en) * | 2018-03-02 | 2020-09-29 | Elicio Therapeutics Inc | Compounds including a mutant kras sequence and a lipid and uses thereof |
AU2019255765A1 (en) * | 2018-04-19 | 2020-12-10 | Board Of Regents, The University Of Texas System | Therapeutic modulation of tumor suppressors using exosomes |
WO2019226612A1 (en) * | 2018-05-21 | 2019-11-28 | The United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating rsv-infections |
CA3147701A1 (en) * | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
CN110835644B (en) * | 2019-12-16 | 2021-08-17 | 广州市宝创生物技术有限公司 | K-ras gene mutation site detection kit |
CN112980840A (en) * | 2019-12-17 | 2021-06-18 | 南京大学 | Multi-targeted siRNA for cancer therapy |
KR102574252B1 (en) * | 2020-12-15 | 2023-09-07 | 주식회사 시선테라퓨틱스 | Composition for Preventing or Treating Pancreatic Cancer Comprising Peptide Nucleic Acid Complex |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050288242A1 (en) * | 2001-05-18 | 2005-12-29 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA) |
WO2005044981A2 (en) * | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
CN101563104A (en) * | 2006-02-01 | 2009-10-21 | 约翰霍普金斯大学 | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
HUE033007T2 (en) * | 2006-06-23 | 2017-11-28 | Engeneic Molecular Delivery Pty Ltd | Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells |
US8252526B2 (en) * | 2006-11-09 | 2012-08-28 | Gradalis, Inc. | ShRNA molecules and methods of use thereof |
WO2008137066A1 (en) * | 2007-05-02 | 2008-11-13 | The Board Of Regents Of The University Of Oklahoma | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
WO2009108217A2 (en) | 2007-09-18 | 2009-09-03 | Intradigm Corporation | Compositions comprising k-ras sirna and methods of use |
AU2010313441B2 (en) | 2009-10-30 | 2013-05-02 | Baylor College Of Medicine | Novel therapeutic RNA interference technology targeted to the PDX-1 oncogene in PDX-1 expressing neuroendocrine tumors |
AR091004A1 (en) * | 2012-05-09 | 2014-12-30 | Gradalis Inc | RNA IN SHORT BIFUNCTIONAL FORK (BI-ARNHC) SPECIFIC OF INDIVIDUAL NUCLEOTID MUTATIONS IN K-RAS |
-
2013
- 2013-05-09 AR ARP130101611A patent/AR091004A1/en unknown
- 2013-05-09 JP JP2015511715A patent/JP6283661B2/en active Active
- 2013-05-09 EP EP13788485.4A patent/EP2847333A4/en active Pending
- 2013-05-09 CA CA2872930A patent/CA2872930A1/en not_active Abandoned
- 2013-05-09 CN CN201380036406.9A patent/CN104685055A/en active Pending
- 2013-05-09 TW TW102116636A patent/TW201402813A/en unknown
- 2013-05-09 SG SG11201407239SA patent/SG11201407239SA/en unknown
- 2013-05-09 KR KR1020147034469A patent/KR20150006477A/en not_active Application Discontinuation
- 2013-05-09 US US13/890,957 patent/US9353373B2/en active Active
- 2013-05-09 AU AU2013259387A patent/AU2013259387B2/en not_active Ceased
- 2013-05-09 WO PCT/US2013/040407 patent/WO2013170071A1/en active Application Filing
- 2013-05-09 MX MX2014013475A patent/MX2014013475A/en unknown
-
2014
- 2014-11-03 IL IL235486A patent/IL235486A0/en unknown
-
2016
- 2016-04-28 US US15/141,280 patent/US20160333351A1/en not_active Abandoned
-
2017
- 2017-07-05 JP JP2017131718A patent/JP2017221198A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2013170071A1 (en) | 2013-11-14 |
US9353373B2 (en) | 2016-05-31 |
JP6283661B2 (en) | 2018-02-21 |
JP2017221198A (en) | 2017-12-21 |
AU2013259387A1 (en) | 2014-11-20 |
CA2872930A1 (en) | 2013-11-14 |
EP2847333A4 (en) | 2015-12-16 |
MX2014013475A (en) | 2015-05-15 |
EP2847333A1 (en) | 2015-03-18 |
US20130302407A1 (en) | 2013-11-14 |
US20160333351A1 (en) | 2016-11-17 |
CN104685055A (en) | 2015-06-03 |
TW201402813A (en) | 2014-01-16 |
AR091004A1 (en) | 2014-12-30 |
AU2013259387B2 (en) | 2016-12-15 |
IL235486A0 (en) | 2014-12-31 |
KR20150006477A (en) | 2015-01-16 |
JP2015521040A (en) | 2015-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407239SA (en) | BI-FUNCTIONAL SHORT-HAIRPIN RNA (BI-SHRNA) SPECIFIC FOR SINGLE-NUCLEOTIDE <i>KRAS</i> MUTATIONS | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201807489PA (en) | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201806663TA (en) | Closed-ended linear duplex dna for non-viral gene transfer | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201407370QA (en) | Humanized il-7 rodents | |
SG11201408385TA (en) | Methods of detecting diseases or conditions | |
SG11201806861SA (en) | Combination therapy with anti-cd73 antibodies | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201407702XA (en) | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription | |
SG11201804372PA (en) | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 | |
SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
SG11201408303WA (en) | Adhesive compositions of propylene-based and ethylene-based polymers | |
SG11201407017WA (en) | Site-specific labeling methods and molecules produced thereby | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201407427WA (en) | Extreme pcr | |
SG11201407610WA (en) | Cd33 antibodies and use of same to treat cancer | |
SG11201407890VA (en) | Tetrahydropyrazolopyrimidine compounds | |
SG11201407802WA (en) | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport |